Brochure
14 Sep 2026
Xellia Pharmaceuticals Sustainability Report
PDF 910 kB
Sustainability, the way we do everything else - honestly.
We make medicines that save lives. That's a responsibility we take seriously, in every direction — including the one that points toward the planet and the people we share it with.
Our 2025 Sustainability Report is out, and it tells a simple story: we're doing the work. Real numbers, real progress, real accountability — from our fermentation tanks in Copenhagen to our production lines in Budapest and Taizhou.
No greenwashing. No vague promises. Just a clear, honest look at where we stand and where we're headed — reviewed and signed off by our Executive Management team, because this matters enough to get right from the top.
Content provided by our supplier
Xellia Pharmaceuticals ApS
-
Country/Region:Denmark
-
Founded:1903
-
On CPHI since:2015
-
Certificates:4
-
Employees:1000 - 4999
Company types
Primary activities
Other Content from Xellia Pharmaceuticals ApS (2)
-
Datasheet Xellia Corporate Introduction
Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers. -
Video Xellia Pharmaceuticals - We're your people
We are more than an API company. We are built on long standing relationships that have stood the test of time. Why? Because for 120 years we have been developing the anti-infectives the world needs. But we are evolving and in the future, we won't be known just for anti-infectives. Our ambition? To be the leading global supplier of APIs across many therapeutic areas.